`___________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________________________
`
`MYLAN PHARMACEUTICALS INC. and
`AMNEAL PHARMACEUTICALS LLC,
`
`Petitioners
`
`v.
`
`YEDA RESEARCH AND DEVELOPMENT CO. LTD.
`
`Patent Owner
`____________________________
`
`Case No. IPR2015-00643 (8,232,250 B2)
`Case No. IPR2015-00644 (8,399,413 B2)
`Case No. IPR2015-00830 (8,969,302 B2)1,2
`____________________________
`
`REQUEST FOR ORAL ARGUMENT
`
`
`
`
`
`
`1 Case Nos. IPR2015-01976, IPR2015-01980 and IPR2015-01981 have been
`
`joined with these proceedings.
`
`2 An identical Request is being filed in each proceeding.
`
`
`
`
`
`
`
`Pursuant to the Board’s Scheduling Orders3 and the Stipulation Regarding
`
`Due Dates Nos. 2, 4 and 54, Petitioners Mylan Pharmaceuticals Inc. and Amneal
`
`Pharmaceuticals LLC. (collectively, “Petitioners”) respectfully request oral
`
`argument, currently scheduled for May 12, 2016.
`
`Pursuant to 37 C.F.R. § 42.70(a), Petitioners intend to argue the following
`
`issues:
`
`1.
`
`Any issues addressed by Petitioners, including in the Petition for Inter
`
`Partes Review and Reply in any of the proceedings, including whether
`
`any claim of U.S. Patent No. 8,232,250; U.S. Patent No. 8,399,413;
`
`and/or U.S. Patent No. 8,969,302 are patentable.
`
`2.
`
`Any issues properly raised by Patent Owner, including in Patent
`
`Owner’s Responses.
`
`Rebuttal to issues raised by Patent Owner.
`
`Petitioners’ motions to exclude evidence.
`
`Any motions to exclude evidence by Patent Owner.
`
`Any issues properly raised in Patent Owner’s Request for Oral
`
`3.
`
`4.
`
`5.
`
`6.
`
`Argument.
`
`
`
`3 IPR2015-00643, Paper 14; IPR2015-00644, Paper 15, IPR2015-00830, Paper 9.
`
`4 IPR2015-00643, Paper 50; IPR2015-00644, Paper 51, IPR2015-00830, Paper 45.
`
`
`
`
`
`
`
`Petitioners request that oral argument in IPR2015-00643, IPR2105-00644
`
`and IPR2015-00830 be combined into a single argument, with each side having 60
`
`minutes for oral argument. Petitioners also request the ability to use audio/visual
`
`equipment to display demonstrative exhibits, including the use of a projector and
`
`screen for a PowerPoint presentation. Because of the number of anticipated
`
`attendees at the hearing, Petitioners request that the largest hearing room available
`
`be reserved for the hearing.
`
`
`
`Dated: April 13, 2016
`
`
`
`/Brandon M. White/ .
`Brandon M. White Reg. No. 52,354
`PERKINS COIE LLP
`700 13th Street, NW, Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6204
`Facsimile: (202) 654-6211
`Email: bmwhite@perkinscoie.com
`Attorney for Mylan Pharmaceuticals Inc.
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing Request for Oral
`
`Argument was served electronically via email as follows:
`
`Patent Owners:
`
`Elizabeth Holland
`Goodwin Procter LLP
`eholland@goodwinprocter.com
`
`William James
`Goodwin Procter LLP
`wjames@goodwinprocter.com
`
`Eleanor Yost
`Goodwin Procter LLP
`eyost@goodwinprocter.com
`
`Nicholas Mitrokostas
`Goodwin Procter LLP
`nmitrokostas@goodwinprocter.com
`
`Daryl Wiesen
`Goodwin Procter LLP
`dwiesen@goodwinprocter.com
`
`John Bennett
`Goodwin Procter LLP
`jbennett@goodwinprocter.com
`
`Petitioner Amneal Pharmaceuticals, LLC:
`
`Vincent L. Capuano
`Duane Morris LLC
`VCapuano@duanemorris.com
`
`Christopher S. Kroon
`Duane Morris LLC
`CSKroon@duanemorris.com
`
`
`Dated: April 13, 2016
`
`
`
`
`
`
`
`
`
`/Brandon M. White/ .
`Brandon M. White
`
`Attorney for Mylan Pharmaceuticals Inc.